GH Research

GH Research is a clinical-stage biotech developing GH001, an inhaled 5‑MeO-DMT therapy for treatment-resistant depression and psychiatric disorders.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series B
Initial Investment Year
2021
GH Research Hover Image